A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL

NCT06779435 · clinicaltrials.gov ↗

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

DLBCL

Interventions

DRUG: Low intensity treatment options
DRUG: Conventional immunochemotherapy regimen

Sponsor

Ruijin Hospital